STOCKS TELEGRAPH

Tag: MMSI

  • 3 Stocks Getting Market Buzz: Merit Medical Systems (MMSI), Tonix Pharmaceuticals (TNXP), Cardiol Therapeutics (CRDL)

    3 Stocks Getting Market Buzz: Merit Medical Systems (MMSI), Tonix Pharmaceuticals (TNXP), Cardiol Therapeutics (CRDL)

    Current market trends highlight a move toward more disciplined investment strategies, with a focus on firms that offer clear visibility into future performance. In biotech, this is amplified by the impact of clinical developments and regulatory updates, which frequently drive sharp movements in share prices.

    Merit Medical Systems, Inc (MMSI)

    Merit Medical Systems, Inc (NASDAQ: MMSI) opened the trading on April 16, 2026, with a bit cautious approach as it glided -0.89% to $70.1. During the day, the stock rose to $70.95 and sunk to $69.76. Taking a more long-term approach, MMSI posted a 52-week range of $66.34-$100.19.

    Nevertheless, stock’s Earnings Per Share (EPS) this year is 5.41%. This publicly-traded company’s shares outstanding now amounts to $59.42 million, simultaneously with a float of $58.22 million. The organization now has a market capitalization sitting at $4.18 billion.

    Tonix Pharmaceuticals Holding Corp (TNXP)

    Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) started the day on April 16, 2026, with a price decrease of -1.46% at $14.13. During the day, the stock rose to $14.52 and sunk to $13.46. Taking a more long-term approach, TNXP posted a 52-week range of $11.60-$69.97.

    It was noted that the giant of the Healthcare sector posted annual sales growth of 86.72% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 86.72%.  Nevertheless, stock’s Earnings Per Share (EPS) this year is 40.08%. This publicly-traded company’s shares outstanding now amounts to $13.41 million, simultaneously with a float of $13.40 million. The organization now has a market capitalization sitting at $189.42 million.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is extending its strategic reach through the development of next-generation therapies designed to address large-scale cardiovascular conditions, particularly heart failure. By advancing beyond its lead oral therapy, the company is positioning itself to capture opportunities in significantly larger markets with high unmet need.

    Market Momentum

    As of April 16, 2026, CRDL closed at $1.41, down 1.40%, with trading volume (330,690 shares) below its average of 581,219 shares—indicating lighter trading activity and short-term consolidation. With a market cap of $157.469M, the stock remains within its 52-week range ($0.8800–$1.5900). A 1-year target estimate of $7.53 continues to reflect meaningful upside potential, supported by ongoing pipeline development.

    Pipeline Expansion: CRD-38

    Cardiol is developing CRD-38 as a subcutaneous therapy aimed at treating heart failure, including HFpEF. This next-generation drug is designed for more convenient dosing and broader clinical use, targeting both inflammation and fibrosis—two key drivers of heart failure progression.

    Strategic Importance

    Heart failure represents a multi-billion-dollar global market with millions of patients and limited therapies addressing inflammatory pathways. By advancing CRD-38, Cardiol is positioning itself to enter this large and underserved space, significantly expanding its long-term commercial opportunity beyond niche indications.

    Outlook

    As CRD-38 progresses toward clinical development, it has the potential to transform Cardiol’s growth profile. Success in heart failure could elevate the company from a single-asset story to a diversified cardiovascular innovator.

  • Early Morning Vibes: 4 Stocks We Like for Tuesday Trading

    Early Morning Vibes: 4 Stocks We Like for Tuesday Trading

    Major US stock indices fell 1.3-1.5% on the first day of trading in 2021.

    The broad market S&P 500 index fell 1.48% to 3700.65 points, the industrial Dow Jones Industrial Average fell 1.25% to 30223.89 points, and the technological NASDAQ dropped 1.47% 12698.45 points.
     

    Despite the general optimistic sentiment of investors regarding the recovery of the global economy after the coronavirus pandemic, the indices declined.

    At the start of the new year, investors focused on the same issue that has dominated the markets for much of 2020: the coronavirus pandemic. Many expect economic activity to accelerate later this year as communities are vaccinated, and organizations reopened. At the same time, there is an understanding that the path to economic recovery will be long and uneven.

    Recent news on the coronavirus situation paints a bleak picture. In the United States, the number of hospitalizations on Sunday reached a record high. In several countries in Europe, governments are extending quarantine restrictions designed to slow the spread of infection.

    The difficulty in dealing with the pandemic means that many companies will be vulnerable to financial risks in the short term.

    The experts noted growing nervousness over the results of the second round of elections to the U.S. Senate in Georgia. The outcome of the vote will determine whether the Republicans will retain control of the Senate. According to investors in prediction markets, the likelihood of a GOP victory has diminished in the past few days, potentially signaling a tense battle for Senate seats.

    Corporate Highlights

    Coca-Cola shares lost 3.8%. RBC Capital Markets has downgraded their rating from “above sector” to “par with the sector.” The bank’s analysts believe that the pandemic will continue to restrict public events and consumer access to restaurants, negatively affecting demand for Coca-Cola products.

    Airline stocks, which were also seriously affected by the coronavirus, also declined on Monday. In particular, American Airlines shares fell 4.1%, while Delta Air Lines shares fell 3.7%.

    Hotel chain shares were also down, with Hilton Worldwide Holdings down 3.4%, while Marriott International shed 5.4%.

    Tesla, meanwhile, gained 3.4%. The electric vehicle maker said it delivered a record 499,550 vehicles last year, just slightly below its target of 500,000.

    Amid a massive sell-off in shares, gold prices jumped 2.7% to $ 1,944.70 per troy ounce, the most significant percentage gain since April. Precious metal quotes usually receive support when market volatility increases.

    An additional source of joy in the market was the latest data on the manufacturing sector’s state. According to surveys of purchasing managers, factories in Asia and Europe increased their output at the end of the year. In December, there was a substantial rise in activity.

    Today Top Movers

    ‎Jaguar Health Inc (JAGX) share price ascended 30.90% to $2.33 during early morning ‎trading session on Tuesday.‎ ‎

    Zosano Pharma Corp (ZSAN), a Biotechnology company, increased about 78.60% ‎at ‎‎$1.04 in pre-market trading Tuesday after declaring that the company requested a Type A meeting with the U.S. Food and Drug Administration (FDA) to review resubmission plans for Qtrypta new drug application. ‎

    Naked Brand Group Ltd (NAKD) stock surged 14.83% at $0.25 in the pre-market trading today.

    Broadway Fin Cp (BYFC) jumped over 46.88% at $2.82 in pre-market ‎trading on Tuesday after the company and CFBanc Corporation revealed receipt of regulatory approvals for the merger.

    Top Upgrades & Downgrades


    Needham turned bullish on Merit Medical Systems Inc. (MMSI), upgrading the stock to “Buy” and assigning a $65.0 price target, representing potential upside of 18.69% from Monday’s close.
     

    DocuSign Inc. (DOCU) has won the favor of Piper Sandler’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $300.
     

    Cadence Design Systems Inc. (CDNS) received an upgrade from analysts at KeyBanc, who also set their one-year price target on the stock to $155.0. They changed their rating on CDNS to Overweight from Sector Weight in a recently issued research note.
     

    Earlier Sunday Piper Sandler reduced its rating on Fortinet Inc. (FTNT) stock to Neutral from Overweight.
     

    Piper Sandler analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Rapid7 Inc. (RPD) has been changed to Neutral from Overweight and the new price target is set at $95.
     

    Analysts at Piper Sandler downgraded Okta Inc. (OKTA)’s stock to Neutral from Overweight on Tuesday.

    Latest Insider Activity

    ReneSola Ltd (SOL) CFO SHAH CAPITAL MANAGEMENT announced the sale of shares taking place on Dec 31 at $11.90 for some 26,000 shares. The total came to more than $0.31 million.
     

    ACM Research Inc. (ACMR) Wang Jian sold on Dec 30 a total 84,386 shares at $78.00 on average. The insider’s sale generated proceeds of almost $2.53 million.
     

    Hall of Fame Resort & Entertainment Company (HOFV) Director Lichter Stuart declared the purchase of shares taking place on Dec 29 at $1.40 for some 10,813,774 shares. The transaction amount was around $15.14 million.
     

    Beyond Air Inc. (XAIR) CEO, Chairman Lisi Steven A. bought on Dec 31 a total 929 shares at $5.28 on average. The purchase cost the insider an estimated $203,280.

    Important Earnings

    Top US earnings releases scheduled for today include Cal-Maine Foods Inc. (NASDAQ:CALM). It will announce its Nov 2020 financial results. The company is expected to report earnings of -$0.08 per share from revenues of $333.49M in the three-month period.